ES2617861T3 - Derivados de ácido 7-oxo-tiazolopiridín-carbónico y utilización de los mismos en el tratamiento, mejora o prevención de una enfermedad vírica - Google Patents
Derivados de ácido 7-oxo-tiazolopiridín-carbónico y utilización de los mismos en el tratamiento, mejora o prevención de una enfermedad vírica Download PDFInfo
- Publication number
- ES2617861T3 ES2617861T3 ES13730130.5T ES13730130T ES2617861T3 ES 2617861 T3 ES2617861 T3 ES 2617861T3 ES 13730130 T ES13730130 T ES 13730130T ES 2617861 T3 ES2617861 T3 ES 2617861T3
- Authority
- ES
- Spain
- Prior art keywords
- optionally substituted
- oxo
- virus
- 4alkyl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 8
- 201000010099 disease Diseases 0.000 title description 7
- 230000003612 virological effect Effects 0.000 title description 6
- 230000002265 prevention Effects 0.000 title description 2
- JKFBHDDZCFQQOE-UHFFFAOYSA-N carbonic acid;2h-[1,3]thiazolo[5,4-b]pyridin-7-one Chemical class OC(O)=O.O=C1C=CN=C2SCN=C12 JKFBHDDZCFQQOE-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract description 96
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 9
- 125000003107 substituted aryl group Chemical group 0.000 abstract 9
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 8
- 229910052760 oxygen Inorganic materials 0.000 abstract 8
- 229910052717 sulfur Inorganic materials 0.000 abstract 7
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 229940002612 prodrug Drugs 0.000 abstract 3
- 239000000651 prodrug Substances 0.000 abstract 3
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 229940126523 co-drug Drugs 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 86
- 238000000034 method Methods 0.000 description 63
- -1 biphenyl-2-ylmethyl Chemical group 0.000 description 60
- 239000007787 solid Substances 0.000 description 50
- 238000005160 1H NMR spectroscopy Methods 0.000 description 27
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 26
- 239000000843 powder Substances 0.000 description 19
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- 241000700605 Viruses Species 0.000 description 13
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 239000000203 mixture Substances 0.000 description 11
- 239000002253 acid Substances 0.000 description 10
- DFNYGALUNNFWKJ-UHFFFAOYSA-N aminoacetonitrile Chemical compound NCC#N DFNYGALUNNFWKJ-UHFFFAOYSA-N 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 7
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 7
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- 125000004494 ethyl ester group Chemical group 0.000 description 6
- FQYYIPZPELSLDK-UHFFFAOYSA-N ethyl pyridine-2-carboxylate Chemical compound CCOC(=O)C1=CC=CC=N1 FQYYIPZPELSLDK-UHFFFAOYSA-N 0.000 description 6
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- MASZNIUZKMPEKE-UHFFFAOYSA-N 4-chloro-2-fluorobenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=C(Cl)C=C1F MASZNIUZKMPEKE-UHFFFAOYSA-N 0.000 description 4
- MSFQEZBRFPAFEX-UHFFFAOYSA-N 4-methoxybenzenesulfonamide Chemical compound COC1=CC=C(S(N)(=O)=O)C=C1 MSFQEZBRFPAFEX-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- YPOXGDJGKBXRFP-UHFFFAOYSA-N pyrimidine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC=N1 YPOXGDJGKBXRFP-UHFFFAOYSA-N 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- IDPURXSQCKYKIJ-UHFFFAOYSA-N 1-(4-methoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C=C1 IDPURXSQCKYKIJ-UHFFFAOYSA-N 0.000 description 3
- 102000004533 Endonucleases Human genes 0.000 description 3
- 108010042407 Endonucleases Proteins 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 241000712907 Retroviridae Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 235000011181 potassium carbonates Nutrition 0.000 description 3
- 241000712461 unidentified influenza virus Species 0.000 description 3
- AKGJLIXNRPNPCH-UHFFFAOYSA-N (2,5-dichlorophenyl)methanamine Chemical compound NCC1=CC(Cl)=CC=C1Cl AKGJLIXNRPNPCH-UHFFFAOYSA-N 0.000 description 2
- KDDNKZCVYQDGKE-UHFFFAOYSA-N (2-chlorophenyl)methanamine Chemical compound NCC1=CC=CC=C1Cl KDDNKZCVYQDGKE-UHFFFAOYSA-N 0.000 description 2
- BJFPYGGTDAYECS-UHFFFAOYSA-N (3-chlorophenyl)methanamine Chemical compound NCC1=CC=CC(Cl)=C1 BJFPYGGTDAYECS-UHFFFAOYSA-N 0.000 description 2
- YMVFJGSXZNNUDW-UHFFFAOYSA-N (4-chlorophenyl)methanamine Chemical compound NCC1=CC=C(Cl)C=C1 YMVFJGSXZNNUDW-UHFFFAOYSA-N 0.000 description 2
- SEXZHJJUKFXNDY-UHFFFAOYSA-N 1-(bromomethyl)-2-phenylbenzene Chemical group BrCC1=CC=CC=C1C1=CC=CC=C1 SEXZHJJUKFXNDY-UHFFFAOYSA-N 0.000 description 2
- RQEUFEKYXDPUSK-UHFFFAOYSA-N 1-phenylethylamine Chemical compound CC(N)C1=CC=CC=C1 RQEUFEKYXDPUSK-UHFFFAOYSA-N 0.000 description 2
- JFNGNNKVPCZQNG-UHFFFAOYSA-N 2-[(3-fluorophenyl)sulfonylamino]-7-oxo-4-[(2-phenylphenyl)methyl]-[1,3]thiazolo[5,4-b]pyridine-6-carboxylic acid Chemical compound C1=2SC(NS(=O)(=O)C=3C=C(F)C=CC=3)=NC=2C(=O)C(C(=O)O)=CN1CC1=CC=CC=C1C1=CC=CC=C1 JFNGNNKVPCZQNG-UHFFFAOYSA-N 0.000 description 2
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical compound BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 2
- ZREOVNLSUMOOGE-UHFFFAOYSA-N 4-[2-(4-chlorophenyl)ethyl]-2-cyclopropyl-7-oxopyrazolo[1,5-a]pyrimidine-6-carboxylic acid Chemical compound C12=CC(C3CC3)=NN2C(=O)C(C(=O)O)=CN1CCC1=CC=C(Cl)C=C1 ZREOVNLSUMOOGE-UHFFFAOYSA-N 0.000 description 2
- HHHDJHHNEURCNV-UHFFFAOYSA-N 4-chlorobenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=C(Cl)C=C1 HHHDJHHNEURCNV-UHFFFAOYSA-N 0.000 description 2
- UZECCNDOASGYNH-UHFFFAOYSA-N 4-cyanobenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=C(C#N)C=C1 UZECCNDOASGYNH-UHFFFAOYSA-N 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000700586 Herpesviridae Species 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- XEPHLZYGRAVQMD-UHFFFAOYSA-N N=1N2C(=O)C(CC(=O)OCC)=CNC2=CC=1C1CC1 Chemical compound N=1N2C(=O)C(CC(=O)OCC)=CNC2=CC=1C1CC1 XEPHLZYGRAVQMD-UHFFFAOYSA-N 0.000 description 2
- 241001631646 Papillomaviridae Species 0.000 description 2
- 241000711504 Paramyxoviridae Species 0.000 description 2
- 241000709664 Picornaviridae Species 0.000 description 2
- 102000029797 Prion Human genes 0.000 description 2
- 108091000054 Prion Proteins 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 102220517071 Transcriptional regulator PINT87aa_I10A_mutation Human genes 0.000 description 2
- 102220517058 Transcriptional regulator PINT87aa_I11A_mutation Human genes 0.000 description 2
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- SOLJWFZRAWWNCI-UHFFFAOYSA-N ethyl 2-cyclopropyl-7-oxo-4-(2-phenylethyl)pyrazolo[1,5-a]pyrimidine-6-carboxylate Chemical compound C12=CC(C3CC3)=NN2C(=O)C(C(=O)OCC)=CN1CCC1=CC=CC=C1 SOLJWFZRAWWNCI-UHFFFAOYSA-N 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- GMGURIXOPQPLIV-UHFFFAOYSA-N (3-fluorophenyl)methanesulfonamide Chemical compound NS(=O)(=O)CC1=CC=CC(F)=C1 GMGURIXOPQPLIV-UHFFFAOYSA-N 0.000 description 1
- OOKAZRDERJMRCJ-KOUAFAAESA-N (3r)-7-[(1s,2s,4ar,6s,8s)-2,6-dimethyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-3-hydroxy-5-oxoheptanoic acid Chemical compound C1=C[C@H](C)[C@H](CCC(=O)C[C@@H](O)CC(O)=O)C2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C[C@@H]21 OOKAZRDERJMRCJ-KOUAFAAESA-N 0.000 description 1
- XRNVSPDQTPVECU-UHFFFAOYSA-N (4-bromophenyl)methanamine Chemical compound NCC1=CC=C(Br)C=C1 XRNVSPDQTPVECU-UHFFFAOYSA-N 0.000 description 1
- DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 description 1
- VQHPRVYDKRESCL-UHFFFAOYSA-N 1-bromoadamantane Chemical compound C1C(C2)CC3CC2CC1(Br)C3 VQHPRVYDKRESCL-UHFFFAOYSA-N 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- MYOUHONFMXUKQJ-UHFFFAOYSA-N 2,4-dichlorobenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=C(Cl)C=C1Cl MYOUHONFMXUKQJ-UHFFFAOYSA-N 0.000 description 1
- WGFNXGPBPIJYLI-UHFFFAOYSA-N 2,6-difluoro-3-[(3-fluorophenyl)sulfonylamino]-n-(3-methoxy-1h-pyrazolo[3,4-b]pyridin-5-yl)benzamide Chemical compound C1=C2C(OC)=NNC2=NC=C1NC(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC(F)=C1 WGFNXGPBPIJYLI-UHFFFAOYSA-N 0.000 description 1
- 125000000301 2-(3-chlorophenyl)ethyl group Chemical group [H]C1=C([H])C(=C([H])C(Cl)=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- RVHXHSAYKUNCDL-UHFFFAOYSA-N 2-[(4-chloro-2-fluorophenyl)sulfonylamino]-7-oxo-4-[(2-phenylphenyl)methyl]-[1,3]thiazolo[5,4-b]pyridine-6-carboxylic acid Chemical compound C1=2SC(NS(=O)(=O)C=3C(=CC(Cl)=CC=3)F)=NC=2C(=O)C(C(=O)O)=CN1CC1=CC=CC=C1C1=CC=CC=C1 RVHXHSAYKUNCDL-UHFFFAOYSA-N 0.000 description 1
- WEBAJCFOCYIBIQ-UHFFFAOYSA-N 2-[(4-chlorophenyl)methylsulfonylamino]-7-oxo-4-[(2-phenylphenyl)methyl]-[1,3]thiazolo[5,4-b]pyridine-6-carboxylic acid Chemical compound C1=2SC(NS(=O)(=O)CC=3C=CC(Cl)=CC=3)=NC=2C(=O)C(C(=O)O)=CN1CC1=CC=CC=C1C1=CC=CC=C1 WEBAJCFOCYIBIQ-UHFFFAOYSA-N 0.000 description 1
- SCRAKOSXXINUOI-UHFFFAOYSA-N 2-[(4-methoxyphenyl)sulfonylamino]-7-oxo-4-[(2-phenylphenyl)methyl]-[1,3]thiazolo[5,4-b]pyridine-6-carboxylic acid Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)NC1=NC(C(C(C(O)=O)=CN2CC=3C(=CC=CC=3)C=3C=CC=CC=3)=O)=C2S1 SCRAKOSXXINUOI-UHFFFAOYSA-N 0.000 description 1
- PAYROHWFGZADBR-UHFFFAOYSA-N 2-[[4-amino-5-(5-iodo-4-methoxy-2-propan-2-ylphenoxy)pyrimidin-2-yl]amino]propane-1,3-diol Chemical compound C1=C(I)C(OC)=CC(C(C)C)=C1OC1=CN=C(NC(CO)CO)N=C1N PAYROHWFGZADBR-UHFFFAOYSA-N 0.000 description 1
- FNKJCDCNCXUIMU-UHFFFAOYSA-N 2-amino-4-(cyclohexylmethyl)-7-oxo-[1,2,4]triazolo[1,5-a]pyrimidine-6-carboxylic acid Chemical compound C1=C(C(O)=O)C(=O)N2N=C(N)N=C2N1CC1CCCCC1 FNKJCDCNCXUIMU-UHFFFAOYSA-N 0.000 description 1
- BXORYBORSAIRBS-UHFFFAOYSA-N 2-amino-4-benzyl-7-oxo-[1,2,4]triazolo[1,5-a]pyrimidine-6-carboxylic acid Chemical compound C1=C(C(O)=O)C(=O)N2N=C(N)N=C2N1CC1=CC=CC=C1 BXORYBORSAIRBS-UHFFFAOYSA-N 0.000 description 1
- XIHOQYGRMJPATB-UHFFFAOYSA-N 2-amino-7-oxo-4-(2-phenylethyl)-[1,2,4]triazolo[1,5-a]pyrimidine-6-carboxylic acid Chemical compound C1=C(C(O)=O)C(=O)N2N=C(N)N=C2N1CCC1=CC=CC=C1 XIHOQYGRMJPATB-UHFFFAOYSA-N 0.000 description 1
- HDISSDCRCIQIIC-UHFFFAOYSA-N 2-amino-7-oxo-4-[(2-phenylphenyl)methyl]-[1,2,4]triazolo[1,5-a]pyrimidine-6-carboxylic acid Chemical compound C1=C(C(O)=O)C(=O)N2N=C(N)N=C2N1CC1=CC=CC=C1C1=CC=CC=C1 HDISSDCRCIQIIC-UHFFFAOYSA-N 0.000 description 1
- RDXMEEPUYJLLBW-UHFFFAOYSA-N 2-amino-7-oxo-4-propan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidine-6-carboxylic acid Chemical compound CC(C)N1C=C(C(O)=O)C(=O)N2N=C(N)N=C12 RDXMEEPUYJLLBW-UHFFFAOYSA-N 0.000 description 1
- NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 1
- YNUQSAWZNMZNNB-UHFFFAOYSA-N 2-cyclopropyl-4-[2-(3-fluorophenyl)ethyl]-7-oxopyrazolo[1,5-a]pyrimidine-6-carboxylic acid Chemical compound C12=CC(C3CC3)=NN2C(=O)C(C(=O)O)=CN1CCC1=CC=CC(F)=C1 YNUQSAWZNMZNNB-UHFFFAOYSA-N 0.000 description 1
- QBDCHVGPNVPOHN-UHFFFAOYSA-N 2-cyclopropyl-4-[2-(4-hydroxyphenyl)ethyl]-7-oxopyrazolo[1,5-a]pyrimidine-6-carboxylic acid Chemical compound C12=CC(C3CC3)=NN2C(=O)C(C(=O)O)=CN1CCC1=CC=C(O)C=C1 QBDCHVGPNVPOHN-UHFFFAOYSA-N 0.000 description 1
- PHCMTRQADOUDSH-UHFFFAOYSA-N 2-cyclopropyl-7-oxo-4-(2-phenylethyl)pyrazolo[1,5-a]pyrimidine-6-carboxylic acid Chemical compound C12=CC(C3CC3)=NN2C(=O)C(C(=O)O)=CN1CCC1=CC=CC=C1 PHCMTRQADOUDSH-UHFFFAOYSA-N 0.000 description 1
- YTPOYKICJSBYNF-UHFFFAOYSA-N 2-cyclopropyl-7-oxo-4-(3-phenylpropyl)pyrazolo[1,5-a]pyrimidine-6-carboxylic acid Chemical compound C12=CC(C3CC3)=NN2C(=O)C(C(=O)O)=CN1CCCC1=CC=CC=C1 YTPOYKICJSBYNF-UHFFFAOYSA-N 0.000 description 1
- OMSMJEXLNJLOJG-UHFFFAOYSA-N 2-cyclopropyl-7-oxo-4-[2-[3-(trifluoromethyl)phenyl]ethyl]pyrazolo[1,5-a]pyrimidine-6-carboxylic acid Chemical compound C12=CC(C3CC3)=NN2C(=O)C(C(=O)O)=CN1CCC1=CC=CC(C(F)(F)F)=C1 OMSMJEXLNJLOJG-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
- LDVPESAORSHIQK-UHFFFAOYSA-N 4-(1-adamantyl)-2-amino-7-oxo-[1,2,4]triazolo[1,5-a]pyrimidine-6-carboxylic acid Chemical compound C1C(C2)CC(C3)CC2CC13N1C2=NC(N)=NN2C(=O)C(C(O)=O)=C1 LDVPESAORSHIQK-UHFFFAOYSA-N 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- MLNFMFAMNBGAQT-UHFFFAOYSA-N 4-propan-2-yloxyaniline Chemical compound CC(C)OC1=CC=C(N)C=C1 MLNFMFAMNBGAQT-UHFFFAOYSA-N 0.000 description 1
- UCAGLBKTLXCODC-UHFFFAOYSA-M 4-sulfamoylbenzoate Chemical compound NS(=O)(=O)C1=CC=C(C([O-])=O)C=C1 UCAGLBKTLXCODC-UHFFFAOYSA-M 0.000 description 1
- KLCKUJMHTNSQBS-UHFFFAOYSA-N 5-(4-ethoxyphenyl)-1h-pyrazol-3-amine Chemical compound C1=CC(OCC)=CC=C1C1=CC(N)=NN1 KLCKUJMHTNSQBS-UHFFFAOYSA-N 0.000 description 1
- WVORIWCOSAWJJE-UHFFFAOYSA-N 5-(trifluoromethyl)-1h-pyrazol-3-amine Chemical compound NC1=CC(C(F)(F)F)=NN1 WVORIWCOSAWJJE-UHFFFAOYSA-N 0.000 description 1
- MXVAGCQKBDMKPG-UHFFFAOYSA-N 5-cyclopropyl-1h-pyrazol-3-amine Chemical compound N1C(N)=CC(C2CC2)=N1 MXVAGCQKBDMKPG-UHFFFAOYSA-N 0.000 description 1
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 1
- XFZZDIHCNHYESF-UHFFFAOYSA-N 7-amino-1-bromo-4-phenyl-5,7,8,9-tetrahydrobenzo[7]annulen-6-one Chemical compound C=12CC(=O)C(N)CCC2=C(Br)C=CC=1C1=CC=CC=C1 XFZZDIHCNHYESF-UHFFFAOYSA-N 0.000 description 1
- BUHKSVAVVBZSKM-UHFFFAOYSA-N 7-oxo-1h-pyrazolo[1,5-a]pyrimidine-6-carboxylic acid Chemical compound O=C1C(C(=O)O)=CN=C2C=CNN21 BUHKSVAVVBZSKM-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 1
- 241000202702 Adeno-associated virus - 3 Species 0.000 description 1
- 241000701242 Adenoviridae Species 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000712892 Arenaviridae Species 0.000 description 1
- 241001533362 Astroviridae Species 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 1
- 241000776207 Bornaviridae Species 0.000 description 1
- 241001115070 Bornavirus Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- FQZWMBGBGRWWBB-UHFFFAOYSA-N C1=CC(OCC)=CC=C1C1=NN2C(=O)C(CC(O)=O)=CNC2=C1 Chemical compound C1=CC(OCC)=CC=C1C1=NN2C(=O)C(CC(O)=O)=CNC2=C1 FQZWMBGBGRWWBB-UHFFFAOYSA-N 0.000 description 1
- 241000714198 Caliciviridae Species 0.000 description 1
- 241001493160 California encephalitis virus Species 0.000 description 1
- 241001502567 Chikungunya virus Species 0.000 description 1
- 201000003075 Crimean-Congo hemorrhagic fever Diseases 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 241001533413 Deltavirus Species 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- 241001520695 Duvenhage lyssavirus Species 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241000988559 Enterovirus A Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 241000711950 Filoviridae Species 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 241000531123 GB virus C Species 0.000 description 1
- 241000190708 Guanarito mammarenavirus Species 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 241000150562 Hantaan orthohantavirus Species 0.000 description 1
- 241000893570 Hendra henipavirus Species 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000700739 Hepadnaviridae Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000724675 Hepatitis E virus Species 0.000 description 1
- 241000724709 Hepatitis delta virus Species 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 241001122120 Hepeviridae Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 244000309467 Human Coronavirus Species 0.000 description 1
- 241000598171 Human adenovirus sp. Species 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 241000724642 Human astrovirus 1 Species 0.000 description 1
- 241001207270 Human enterovirus Species 0.000 description 1
- 241000713673 Human foamy virus Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000702617 Human parvovirus B19 Species 0.000 description 1
- 241000829111 Human polyomavirus 1 Species 0.000 description 1
- 208000002979 Influenza in Birds Diseases 0.000 description 1
- 241001661732 Isavirus Species 0.000 description 1
- 241000701460 JC polyomavirus Species 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- 241000712890 Junin mammarenavirus Species 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 241000713102 La Crosse virus Species 0.000 description 1
- 241000712902 Lassa mammarenavirus Species 0.000 description 1
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 description 1
- 241000712898 Machupo mammarenavirus Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001480504 Mammalian orthoreovirus 1 Species 0.000 description 1
- 241001480506 Mammalian orthoreovirus 2 Species 0.000 description 1
- 241001115401 Marburgvirus Species 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 241000725171 Mokola lyssavirus Species 0.000 description 1
- 241000700560 Molluscum contagiosum virus Species 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- NURWYRRGLDKRSX-UHFFFAOYSA-N N=1N2C(=O)C(CC(=O)O)=CNC2=CC=1C1CC1 Chemical compound N=1N2C(=O)C(CC(=O)O)=CNC2=CC=1C1CC1 NURWYRRGLDKRSX-UHFFFAOYSA-N 0.000 description 1
- 241000714209 Norwalk virus Species 0.000 description 1
- 241000710944 O'nyong-nyong virus Species 0.000 description 1
- FRWASHLBVRTOKM-UHFFFAOYSA-N O=C1C(CC(=O)O)=CNC2=CC(C(F)(F)F)=NN21 Chemical compound O=C1C(CC(=O)O)=CNC2=CC(C(F)(F)F)=NN21 FRWASHLBVRTOKM-UHFFFAOYSA-N 0.000 description 1
- JJJDUQYIHZKCFP-UHFFFAOYSA-N O=C1C(CC(=O)OCC)=CNC2=C(Br)C(C)=NN21 Chemical compound O=C1C(CC(=O)OCC)=CNC2=C(Br)C(C)=NN21 JJJDUQYIHZKCFP-UHFFFAOYSA-N 0.000 description 1
- JDQORWARSHCXPQ-UHFFFAOYSA-N O=C1C(CC(=O)OCC)=CNC2=CC(C(F)(F)F)=NN21 Chemical compound O=C1C(CC(=O)OCC)=CNC2=CC(C(F)(F)F)=NN21 JDQORWARSHCXPQ-UHFFFAOYSA-N 0.000 description 1
- 241000712464 Orthomyxoviridae Species 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 241000991583 Parechovirus Species 0.000 description 1
- 241000701945 Parvoviridae Species 0.000 description 1
- 241000150350 Peribunyaviridae Species 0.000 description 1
- 241001631648 Polyomaviridae Species 0.000 description 1
- 241000700625 Poxviridae Species 0.000 description 1
- 241000150264 Puumala orthohantavirus Species 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 241000702247 Reoviridae Species 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 241000711931 Rhabdoviridae Species 0.000 description 1
- 241000710942 Ross River virus Species 0.000 description 1
- 241001137860 Rotavirus A Species 0.000 description 1
- 241001137861 Rotavirus B Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 241000149820 Sakhalin orthonairovirus Species 0.000 description 1
- 241000369753 Sapporo virus Species 0.000 description 1
- 241000150278 Seoul orthohantavirus Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 241000710888 St. Louis encephalitis virus Species 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 241000710771 Tick-borne encephalitis virus Species 0.000 description 1
- 241000710924 Togaviridae Species 0.000 description 1
- 241000713152 Uukuniemi virus Species 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 241000710886 West Nile virus Species 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 108700010877 adenoviridae proteins Proteins 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 206010064097 avian influenza Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- UUWSLBWDFJMSFP-UHFFFAOYSA-N bromomethylcyclohexane Chemical compound BrCC1CCCCC1 UUWSLBWDFJMSFP-UHFFFAOYSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 1
- 125000006312 cyclopentyl amino group Chemical group [H]N(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000006317 cyclopropyl amino group Chemical group 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- GEKFSDQHRFPVNL-UHFFFAOYSA-N ethyl 2-(2-cyclopropyl-4-methyl-7-oxopyrazolo[1,5-a]pyrimidin-6-yl)acetate Chemical compound N=1N2C(=O)C(CC(=O)OCC)=CN(C)C2=CC=1C1CC1 GEKFSDQHRFPVNL-UHFFFAOYSA-N 0.000 description 1
- OMUPFVFQLVBZPU-UHFFFAOYSA-N ethyl 2-(benzylamino)-7-oxo-1h-[1,2,4]triazolo[1,5-a]pyrimidine-6-carboxylate Chemical compound N1N2C(=O)C(C(=O)OCC)=CN=C2N=C1NCC1=CC=CC=C1 OMUPFVFQLVBZPU-UHFFFAOYSA-N 0.000 description 1
- UTQKFWVOWMAEAL-UHFFFAOYSA-N ethyl 2-(naphthalen-1-ylmethylamino)-7-oxo-1h-[1,2,4]triazolo[1,5-a]pyrimidine-6-carboxylate Chemical compound C1=CC=C2C(CNC3=NC4=NC=C(C(N4N3)=O)C(=O)OCC)=CC=CC2=C1 UTQKFWVOWMAEAL-UHFFFAOYSA-N 0.000 description 1
- VGCPVNLEDHOHPJ-UHFFFAOYSA-N ethyl 2-[(4-bromophenyl)methylamino]-7-oxo-1h-[1,2,4]triazolo[1,5-a]pyrimidine-6-carboxylate Chemical compound N1N2C(=O)C(C(=O)OCC)=CN=C2N=C1NCC1=CC=C(Br)C=C1 VGCPVNLEDHOHPJ-UHFFFAOYSA-N 0.000 description 1
- VCMLJEKBVWJVMX-UHFFFAOYSA-N ethyl 2-cyclopropyl-4-[2-(4-hydroxyphenyl)ethyl]-7-oxopyrazolo[1,5-a]pyrimidine-6-carboxylate Chemical compound C12=CC(C3CC3)=NN2C(=O)C(C(=O)OCC)=CN1CCC1=CC=C(O)C=C1 VCMLJEKBVWJVMX-UHFFFAOYSA-N 0.000 description 1
- QJULLHHLCIBXHI-UHFFFAOYSA-N ethyl 4-benzyl-2-cyclopropyl-7-oxopyrazolo[1,5-a]pyrimidine-6-carboxylate Chemical compound C12=CC(C3CC3)=NN2C(=O)C(C(=O)OCC)=CN1CC1=CC=CC=C1 QJULLHHLCIBXHI-UHFFFAOYSA-N 0.000 description 1
- JWXGDVBDEDOZDB-UHFFFAOYSA-N ethyl 7-oxo-2-(4-propan-2-yloxyanilino)-1h-[1,2,4]triazolo[1,5-a]pyrimidine-6-carboxylate Chemical compound N=1N2C(=O)C(C(=O)OCC)=CNC2=NC=1NC1=CC=C(OC(C)C)C=C1 JWXGDVBDEDOZDB-UHFFFAOYSA-N 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 1
- ZBELDPMWYXDLNY-UHFFFAOYSA-N methyl 9-(4-bromo-2-fluoroanilino)-[1,3]thiazolo[5,4-f]quinazoline-2-carboximidate Chemical compound C12=C3SC(C(=N)OC)=NC3=CC=C2N=CN=C1NC1=CC=C(Br)C=C1F ZBELDPMWYXDLNY-UHFFFAOYSA-N 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- ABOYDMHGKWRPFD-UHFFFAOYSA-N phenylmethanesulfonamide Chemical compound NS(=O)(=O)CC1=CC=CC=C1 ABOYDMHGKWRPFD-UHFFFAOYSA-N 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 201000010740 swine influenza Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261650713P | 2012-05-23 | 2012-05-23 | |
| US201261650713P | 2012-05-23 | ||
| PCT/EP2013/060633 WO2013174930A2 (en) | 2012-05-23 | 2013-05-23 | 7-oxo-thiazolopyridine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2617861T3 true ES2617861T3 (es) | 2017-06-20 |
Family
ID=48669865
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13730130.5T Active ES2617861T3 (es) | 2012-05-23 | 2013-05-23 | Derivados de ácido 7-oxo-tiazolopiridín-carbónico y utilización de los mismos en el tratamiento, mejora o prevención de una enfermedad vírica |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9434745B2 (enExample) |
| EP (1) | EP2864338B1 (enExample) |
| JP (1) | JP2015517555A (enExample) |
| KR (1) | KR20150009553A (enExample) |
| CN (1) | CN104334563B (enExample) |
| BR (1) | BR112014029016A8 (enExample) |
| CA (1) | CA2874250A1 (enExample) |
| ES (1) | ES2617861T3 (enExample) |
| MX (1) | MX2014014106A (enExample) |
| RU (1) | RU2014143250A (enExample) |
| WO (1) | WO2013174930A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9309250B2 (en) | 2011-06-22 | 2016-04-12 | Vertex Pharmaceuticals Incorporated | Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors |
| KR20150014506A (ko) * | 2012-05-23 | 2015-02-06 | 사피라 파르마슈티칼즈 게엠베하 | 바이러스성 질환의 치료, 개선 또는 예방에서 유용한 7-옥소-4,7-디하이드로-피라졸로[1,5-a]피리미딘 유도체 |
| US20140010783A1 (en) * | 2012-07-06 | 2014-01-09 | Hoffmann-La Roche Inc. | Antiviral compounds |
| PL3808749T3 (pl) | 2012-12-07 | 2023-07-10 | Vertex Pharmaceuticals Incorporated | Pirazolo[1,5-a]pirymidyny użyteczne jako inhibitory kinazy atr do leczenia chorób nowotworowych |
| CN105980386B (zh) | 2013-03-13 | 2021-08-13 | 基因泰克公司 | 吡唑并化合物及其用途 |
| JP2016512815A (ja) | 2013-03-15 | 2016-05-09 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ａｔｒキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体 |
| JP2016512239A (ja) | 2013-03-15 | 2016-04-25 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ａｔｒキナーゼの阻害剤として有用な化合物 |
| EP2970288A1 (en) | 2013-03-15 | 2016-01-20 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| PL3077397T3 (pl) | 2013-12-06 | 2020-04-30 | Vertex Pharmaceuticals Inc. | Związek 2-amino-6-fluoro-n-[5-fluoro-pirydyn-3-ylo]pyrazolo [1,5-a]pirymidino-3-karboksamidu przydatny jako inhibitor kinazy atr, jego wytwarzanie, różne postacie stałe i ich radioznakowane pochodne |
| SG10201902206QA (en) | 2014-06-05 | 2019-04-29 | Vertex Pharma | Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof |
| PT3157566T (pt) | 2014-06-17 | 2019-07-11 | Vertex Pharma | Método para tratamento de cancro utilizando uma combinação de inibidores chk1 e atr |
| CA2953862A1 (en) | 2014-07-07 | 2016-01-14 | F. Hoffmann-La Roche Ag | Dihydropyridopyrazine-1,8-diones and their use in the treatment, amelioration or prevention of viral diseases |
| ES2938877T3 (es) | 2015-04-28 | 2023-04-17 | Shionogi & Co | Derivados de piridona policíclicos sustituidos y profármacos de los mismos |
| EP4219508B1 (en) | 2015-04-28 | 2024-06-05 | Shionogi & Co., Ltd | Substituted polycyclic pyridone derivative and prodrug thereof |
| US20170081331A1 (en) | 2015-09-18 | 2017-03-23 | F. Hoffmann-La Roche Ag | Pyrazolopyrazines and their use in the treatment, amelioration or prevention of a viral disease |
| RU2768621C1 (ru) | 2015-09-30 | 2022-03-24 | Вертекс Фармасьютикалз Инкорпорейтед | Способ лечения рака с использованием комбинации повреждающих днк средств и ингибиторов atr |
| CR20180356A (es) | 2015-12-15 | 2018-08-22 | Shionogi & Co | Un medicamento caracterizado por combinar un inhibidor de la endonucleasa cap-dependiente del virus de la influenza y un fármaco anti-influenza |
| JP6957535B2 (ja) | 2016-06-29 | 2021-11-02 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ピリダジノンベースの広域スペクトル抗インフルエンザ阻害剤 |
| NZ791086A (en) | 2016-08-10 | 2025-08-29 | Shionogi & Co | Substituted polycyclic pyridone derivative and pharmaceutical composition containing prodrug thereof |
| JP2020533376A (ja) | 2017-09-15 | 2020-11-19 | アドゥロ バイオテック，インク． | ピラゾロピリミジノン化合物およびその使用 |
| CN117304133A (zh) * | 2023-09-26 | 2023-12-29 | 华南农业大学 | 一种具有噻唑侧链的截短侧耳素衍生物及其制备方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5475109A (en) | 1994-10-17 | 1995-12-12 | Merck & Co., Inc. | Dioxobutanoic acid derivatives as inhibitors of influenza endonuclease |
| AU4172197A (en) * | 1996-09-10 | 1998-04-02 | Pharmacia & Upjohn Company | 8-hydroxy-7-substituted quinolines as anti-viral agents |
| RU2220960C2 (ru) * | 1997-12-22 | 2004-01-10 | Фармация Энд Апджон Компани | 4-гидрокси-3-хинолинкарбоксамиды и гидразиды, фармацевтическая композиция и способ лечения на их основе |
| US6559145B2 (en) * | 2000-07-12 | 2003-05-06 | Pharmacia & Upjohn Company | Heterocycle carboxamides as antiviral agents |
| US20040176366A1 (en) | 2002-08-30 | 2004-09-09 | Wathen Michael W | Method of preventing or treating atherosclerosis or restenosis |
| JP4953297B2 (ja) | 2004-09-15 | 2012-06-13 | 塩野義製薬株式会社 | Ｈｉｖインテグラーゼ阻害活性を有するカルバモイルピリドン誘導体 |
| TW200716632A (en) | 2005-05-16 | 2007-05-01 | Gilead Sciences Inc | Integrase inhibitor compounds |
| EP2412708A4 (en) | 2009-03-26 | 2014-07-23 | Shionogi & Co | SUBSTITUTED 3-HYDROXY-4-PYRIDONE DERIVATIVE |
| TWI518084B (zh) | 2009-03-26 | 2016-01-21 | 鹽野義製藥股份有限公司 | 哌喃酮與吡啶酮衍生物之製造方法 |
| WO2011000566A2 (en) | 2009-06-30 | 2011-01-06 | Savira Pharmaceuticals Gmbh | Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections |
| KR20150014506A (ko) * | 2012-05-23 | 2015-02-06 | 사피라 파르마슈티칼즈 게엠베하 | 바이러스성 질환의 치료, 개선 또는 예방에서 유용한 7-옥소-4,7-디하이드로-피라졸로[1,5-a]피리미딘 유도체 |
-
2013
- 2013-05-23 US US13/900,964 patent/US9434745B2/en not_active Expired - Fee Related
- 2013-05-23 RU RU2014143250A patent/RU2014143250A/ru not_active Application Discontinuation
- 2013-05-23 JP JP2015513182A patent/JP2015517555A/ja active Pending
- 2013-05-23 EP EP13730130.5A patent/EP2864338B1/en not_active Not-in-force
- 2013-05-23 CA CA2874250A patent/CA2874250A1/en not_active Abandoned
- 2013-05-23 BR BR112014029016A patent/BR112014029016A8/pt not_active IP Right Cessation
- 2013-05-23 WO PCT/EP2013/060633 patent/WO2013174930A2/en not_active Ceased
- 2013-05-23 MX MX2014014106A patent/MX2014014106A/es unknown
- 2013-05-23 ES ES13730130.5T patent/ES2617861T3/es active Active
- 2013-05-23 CN CN201380025120.0A patent/CN104334563B/zh not_active Expired - Fee Related
- 2013-05-23 KR KR1020147032703A patent/KR20150009553A/ko not_active Withdrawn
-
2016
- 2016-08-26 US US15/247,991 patent/US20160362423A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013174930A3 (en) | 2014-01-23 |
| CN104334563A (zh) | 2015-02-04 |
| BR112014029016A8 (pt) | 2018-01-09 |
| EP2864338B1 (en) | 2016-12-14 |
| CN104334563B (zh) | 2017-03-08 |
| WO2013174930A2 (en) | 2013-11-28 |
| CA2874250A1 (en) | 2013-11-28 |
| EP2864338A2 (en) | 2015-04-29 |
| US20130317022A1 (en) | 2013-11-28 |
| RU2014143250A (ru) | 2016-07-20 |
| BR112014029016A2 (pt) | 2017-06-27 |
| MX2014014106A (es) | 2015-09-25 |
| HK1205128A1 (en) | 2015-12-11 |
| US20160362423A1 (en) | 2016-12-15 |
| US9434745B2 (en) | 2016-09-06 |
| JP2015517555A (ja) | 2015-06-22 |
| KR20150009553A (ko) | 2015-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2617861T3 (es) | Derivados de ácido 7-oxo-tiazolopiridín-carbónico y utilización de los mismos en el tratamiento, mejora o prevención de una enfermedad vírica | |
| CN104507481B (zh) | 用于治疗、改善或预防病毒疾病的7‑氧代‑4,7‑二氢‑吡唑并[1,5‑a]嘧啶衍生物 | |
| AU2012339342B2 (en) | Kinase modulating compounds, compositions containing the same and use thereof | |
| JP2018522866A5 (enExample) | ||
| JP2015517555A5 (enExample) | ||
| JP2016518305A5 (enExample) | ||
| BR112013002375B1 (pt) | Composto, processo de preparação do mesmo, composição farmacêutica, e, usos de um composto | |
| AR041346A1 (es) | Derivados de imidazol[1,2-a]pirazinas como inhibidores de quinasas dependientes de ciclinas | |
| RU2012112471A (ru) | Аминотетрагидропираны в качестве ингибиторов дипептидилпептидазы-iv для лечения или предупреждения диабета | |
| JP2013010792A5 (enExample) | ||
| JP2013010793A5 (enExample) | ||
| ES2564010T3 (es) | Composición farmacéutica para tratar o prevenir el glaucoma | |
| JP2015510942A5 (enExample) | ||
| ES2821407T3 (es) | Compuestos de piperidina sustituidos con indol como agentes degradantes de los receptores de estrógenos | |
| AU2013221286B2 (en) | Diaminopyrimidines useful as inhibitors of the human respiratory syncytial virus (RSV) | |
| CN106866548B (zh) | 6-环已甲基嘧啶酮类hiv逆转录酶抑制剂、其制备方法和用途 | |
| RU2421455C2 (ru) | СПОСОБ ПОЛУЧЕНИЯ МЕТИЛ 7-АРИЛКАРБАМОИЛ-6-БЕНЗОИЛ-2-МЕТИЛ-3-ФЕНИЛПИРАЗОЛО[1,5-a]ПИРИМИДИН-5-КАРБОКСИЛАТОВ | |
| JP6170260B2 (ja) | ５−ｈｔ２ｂアンタゴニスト | |
| CN110483417B (zh) | 一种DACOs类NNRTIs氨基酸酯衍生物、其制备方法、药物组合物及应用 | |
| US10131674B2 (en) | Process for preparing Substituted Indole Compounds | |
| RU2015118985A (ru) | Производные имидазопиридина | |
| JP2017514867A5 (enExample) | ||
| HK1205128B (en) | 7-oxo-thiazolopyridine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease | |
| AR110406A1 (es) | 6-amino-5-fluoro-5-(fluorometil)-2,3,4,5-tetrahidropiridin-2-il-fenil-5-(metoxi-d₃)-pirazina-2-carboxamidas y derivados fluorados de las mismas como inhibidores de bace1 | |
| TH144014A (th) | กรรมวิธีการผลิตสำหรับอนุพันธ์ไพริมิดีน |